Clinical Trial Update: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sitravatinib combined with PD-(L)1 inhibitors in advanced or metastatic urothelial carcinoma; the trial is terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Sitravatinib (sitravatinib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Status: TERMINATED | Results posted: 2023-08-24